US WorldMeds to Present Final SPEARHEAD-1 Results for TECELRA® in Late-Breaking Oral Presentation at CTOS 2026
Results from all cohorts of the registrational trial selected for the session "Late Breaking Abstracts and Updates – Can They...
Results from all cohorts of the registrational trial selected for the session "Late Breaking Abstracts and Updates – Can They...
In a laboratory study, antiviral T-cells killed nearly 100% of human liver-derived cancer cells treated with CancerVax’s leading LNP-mRNA formulationLehi,...
The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M...
Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig...
Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patientsFirst Breakthrough Therapy Designation (BTD) for daretabart,...
– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous...
SEATTLE, WA / ACCESS Newswire / November 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage...
COM002 is a first-in-class complement-powered immune engager based on Commit Biologics’ proprietary BiCE™ platform.Anne-Marie Levy Rasmussen appointed Chief Operating Officer...
Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance Study...
SEATTLE, WA / ACCESS Newswire / November 11, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage...
Mount Sinai Researchers to Use Functional Precision Medicine Technology to Support Ex Vivo Immunotherapy Response Research in Bladder CancerMADISON, Wis.,...
HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in...
John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at...
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – ...
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...
Zymeworks CEO Kenneth Galbraith speaks about the company’s progress for in Q3 2026 2026 financial guidance raised to a total...
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering...
Capital efficiency strategy prioritizes CD228V development while seeking separate public listing for SkinJect® and partners to advance Teverelix® PHILADELPHIA, PA...
Company Highlights CD228V as its Principal Development Priority, Proposed SPAC Business Combination at ~ $135 Million Valuation for SkinJect® and...